How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?
AMA Journal of Ethics · 01.04.2024 · 26 (4) · E289-294
DOI: 10.1001/amajethics.2024.289 ↗Kurz gefasst
Fachartikel in der Zeitschrift AMA Journal of Ethics, online erschienen am 01.04.2024. Verfasst von Kavitha Nallathambi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Former senior manager of global public policy at US Pharmacopeia. Hauptthemen laut MEDLINE: Excipients, Glycerol. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Former senior manager of global public policy at US Pharmacopeia.
- Director of regulatory and public policy development at US Pharmacopeia.
Zitieren
APA
Nallathambi, K., & Cadwallader, A. B. (2024). How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?. AMA Journal of Ethics, 26(4), E289-294. https://doi.org/10.1001/amajethics.2024.289
Vancouver
Nallathambi K, Cadwallader AB. How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?. AMA Journal of Ethics. 2024;26(4):E289-294. doi:10.1001/amajethics.2024.289
BibTeX
@article{Nallathambi2024,
author = {Nallathambi, Kavitha and Cadwallader, Amy B},
title = {How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?},
journal = {AMA Journal of Ethics},
year = {2024},
volume = {26},
number = {4},
pages = {E289--294},
doi = {10.1001/amajethics.2024.289}
}
EUVIMED